<DOC>
	<DOCNO>NCT03003247</DOCNO>
	<brief_summary>Efficacy Safety IDP-120 Gel Treatment Acne Vulgaris</brief_summary>
	<brief_title>Efficacy Safety IDP-120 Gel Treatment Acne Vulgaris</brief_title>
	<detailed_description>A Phase 2 , Multi-Center , Randomized , Double-Blind , Vehicle- Controlled , Parallel-Group , Clinical Study Comparing Efficacy Safety IDP-120 Gel Treatment Acne Vulgaris</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Key Male female least 9 year age old ; Written verbal informed consent must obtain . Subjects less age consent must sign assent study parent legal guardian must sign informed consent ( subject reach age consent study reconsented next study visit ) Premenses females woman childbearing potential must negative urine pregnancy test screen visit , negative urine pregnancy test baseline visit . Subjects must willing comply study instruction return clinic require visit . Subjects age consent must accompany parent legal guardian time assent/consent signing . If cleanser , moisturizer sunscreen need study , Subjects must willing use allow cleanser , moisturizers , sunscreen , moisturizer/sunscreen combination product . If subject wear makeup must agree use noncomedogenic makeup . Key Use investigational drug device within 30 day enrollment participation research study concurrent study . Any dermatological condition face could interfere clinical evaluation acne conglobata , acne fulminans , secondary acne , perioral dermatitis , clinically significant rosacea , gramnegative folliculitis . Any underlying disease ( ) dermatological condition face require use interfere topical systemic therapy make evaluation lesion count inconclusive . Subjects facial beard mustache could interfere study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>